Foamix Pharmaceuticals (NASDAQ:FOMX) Announces Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Foamix Pharmaceuticals (NASDAQ:FOMX) released its earnings results on Monday. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.07), Fidelity Earnings reports. Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 75.99%.

Shares of NASDAQ FOMX traded down $0.06 during trading on Tuesday, hitting $3.42. 17,906 shares of the company traded hands, compared to its average volume of 2,007,239. The business’s fifty day moving average is $3.18 and its 200 day moving average is $2.86. Foamix Pharmaceuticals has a fifty-two week low of $1.97 and a fifty-two week high of $4.48. The firm has a market capitalization of $264.76 million, a price-to-earnings ratio of -1.97 and a beta of 1.57.

In other news, CFO Ilan Hadar sold 9,420 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $3.50, for a total transaction of $32,970.00. Following the transaction, the chief financial officer now owns 123,671 shares in the company, valued at $432,848.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.95% of the stock is currently owned by corporate insiders.

Several research firms recently issued reports on FOMX. Cowen set a $30.00 target price on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Monday, September 23rd. HC Wainwright restated a “buy” rating and issued a $11.00 target price (up previously from $10.00) on shares of Foamix Pharmaceuticals in a report on Monday, October 21st. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 22nd. Bank of America restated a “buy” rating and issued a $11.00 target price on shares of Foamix Pharmaceuticals in a report on Friday, August 9th. Finally, ValuEngine upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Foamix Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $15.40.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

Featured Story: Convertible Shares

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.